Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 21:13:53-63.
doi: 10.1515/med-2018-0010. eCollection 2018.

Pharmacoeconomics of three Therapeutic Schemes for Anti-tuberculosis Therapy Induced Liver Injury in China

Yu Chen  1 , Peng Ye  2 , Chongwu Ren  3 , Pengfei Ren  1 , Zheng Ma  1 , Lin Zhang  2 , Wenliang Zhou  3 , Changjie Jiang  3
Affiliations

Pharmacoeconomics of three Therapeutic Schemes for Anti-tuberculosis Therapy Induced Liver Injury in China

Yu Chen et al. Open Med (Wars). .

Abstract

To evaluate the pharmacoeconomics of three therapeutic schemes in treating anti-tuberluosis therapy -induced liver injury (anti-TB DILI).

Methods: In the construction of a decision tree model, the efficacy and safety parameters came from the results of the randomized, controlled trial conducted here, the effect parameters were derived from expert advice, and the cost parameters, such as usage specification, number, and unit price, came from literature, expert advice, and so on.

Results: The cost-effectiveness analysis (CEA) based on the effect degrees showed that bicyclol had the best effect (4.63562). The incremental cost-effectiveness ratio (ICER) (206.03270) of bicyclol was the lowest. The cost-effectiveness ratio of silibinin was the lowest (68.59987). The CEA based on the complete normalization rate showed that bicyclol had the highest complete normalization rate (83.562%), the lowest cost-effectiveness ratio (4.63627), and the smallest ICER (4.63504). Sensitivity analyses proved the robustness of the results.

Conclusions: Bicyclol is the most cost-effective therapy and the preferred choice for treating anti-TB DILI.

Keywords: Anti-TB DILI; Cost-effectiveness analysis; Decision trees analysis; Pharmacoeconomics; Prospective.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Authors state no conflict of interest.

Figures

Figure 1
Figure 1
Decision tree model structure The decision node is represented with “□” and it is the starting point of the decision problem. The state point is represented with “O,” indicating the status that the scheme has met with. The lines drawn from the state point indicate a variety of possible states that may occur; next to them, all status contents are marked, and the degree of possibility for development is expressed by probability. The terminal point of decision is expressed by “Δ,” next to which the assigned value of each effect degree is marked.
Figure 2
Figure 2
Cost-effectiveness frontier
See this image and copyright information in PMC

References

    1. Glaziou P., Floyd K., Weil D., Raviglione M.. TB deaths rank alongside HIV deaths as top infectious killer. Int J. Tuberc Lung Dis. 2016;2:143–144. doi: 10.5588/ijtld.15.0985. - DOI - PubMed
    1. The technical guidance group of the fifth national tuberculosis epidemiological random sampling survey, the office of the fifth national tuberculosis epidemiological random sampling survey, The report of the fifth national tuberculosis epidemiological random sampling survey in 2010. Chin J. Antituberculosis prevention. 2012;8:485–508.
    1. Donglou X., Yu M., Lizhen Z. Diagnostic manual for adverse reactions of antituberculosis drugs. 1st. People’s Medical Publishing House; Beijing: 2009.
    1. Chengwei C.. Pathogenesis and treatment strategies of drug-induced liver injury. Zhonghua Jie He He Hu Xi Za Zhi. 2013;10:726–728. doi: 10.3760/cma.j.issn.1001-0939.2013.10.004. - DOI - PubMed
    1. Heping X., Jin G.. Clinical characteristics of antituberculosis drug-induced liver injury. Chin J. tuberculosis prevention. 2013;7:485–487.

LinkOut - more resources